SABCS 2025: vídeos e entrevistas

56 vídeos do SABCS 2025 publicados por LACOG, NCCN, Oncology Brothers, VJOncology. Atualizado em 20/11/2026.

Ver no OncoTV com filtros

Addressing access barriers and guideline-concordant breast cancer careVJOncology · 30/01/2026 · 1:07 · apoio da indústriaDistinct clinical and molecular features of metastatic lobular breast cancerVJOncology · 30/01/2026 · 3:33 · apoio da indústriaGuideline-based sequencing in metastatic HER2-positive breast cancerVJOncology · 30/01/2026 · 1:10 · apoio da indústriaSABCS 2025: sentinel lymph nodes and next-generation oral SERDsVJOncology · 29/01/2026 · 1:16 · apoio da indústriaPathological characterization of rare tumor types in breast cancerVJOncology · 29/01/2026 · 3:26 · apoio da indústriaECOG-ACRIN EA1131: post-NACT TILs and intrinsic subtype in residual TNBCVJOncology · 29/01/2026 · 2:36 · apoio da indústriaCompassHER2 pCR: baseline TILs & pCR after THP in HER2+ breast cancerVJOncology · 29/01/2026 · 3:11 · apoio da indústriaSelecting patients with breast cancer for neratinib after neoadjuvant HER2 therapyVJOncology · 28/01/2026 · 2:02 · apoio da indústriaReal-world safety of extended adjuvant neratinib: interim NERLYFE dataVJOncology · 28/01/2026 · 2:30 · apoio da indústriaClinical challenges in managing CNS metastases in HER2+ breast cancerVJOncology · 28/01/2026 · 3:04 · apoio da indústriaTUXEDO-3: HER3-DXd after T-DXd in HER2+ breast cancer with CNS involvementVJOncology · 28/01/2026 · 3:00 · apoio da indústriaChallenges and future directions of ADC targets and payloads in breast cancerVJOncology · 20/01/2026 · 1:01 · apoio da indústriaManaging cancer risk in BRCA1 mutation carriers without prior breast cancerVJOncology · 20/01/2026 · 1:34 · apoio da indústriactDNA assays for early detection and prognosis of breast cancer recurrenceVJOncology · 20/01/2026 · 1:32 · apoio da indústriaAdvances and challenges in MRD-guided adjuvant therapy for breast cancerVJOncology · 20/01/2026 · 1:08 · apoio da indústriaIdentifying patients who benefit from extended endocrine therapy in breast cancerVJOncology · 20/01/2026 · 2:44 · apoio da indústriaStrategies to overcome CDK4/6 inhibitor resistance in breast cancerVJOncology · 19/01/2026 · 2:24 · apoio da indústriaPerspectives in CDK4/6 inhibitor resistance in breast cancerVJOncology · 19/01/2026 · 3:46 · apoio da indústriaDendritic cell therapy: immune cell collection and production processVJOncology · 19/01/2026 · 1:13 · apoio da indústriaThe benefits of intrathecal administration of dendritic cells for breast cancerVJOncology · 19/01/2026 · 1:49 · apoio da indústriaIntrathecal cDC1s induce adaptive immunity in leptomeningeal diseaseVJOncology · 19/01/2026 · 6:11 · apoio da indústriaWhat future role will oral SERDs have in early stage breast cancer?VJOncology · 19/01/2026 · 1:26 · apoio da indústriaI-SPY 2 EOP: neoadjuvant vepdegestrant combinations in HR+ breast cancerVJOncology · 19/01/2026 · 5:07 · apoio da indústriaEvaluating the feasibility of ctDNA in monitoring breast cancer treatmentVJOncology · 19/01/2026 · 2:06 · apoio da indústriactDNA biomarkers with vepdegestrant in ER+/HER2- advanced breast cancerVJOncology · 19/01/2026 · 3:03 · apoio da indústriaHER2+ SABCS 2025 Highlights DESTINY Breast-05/Breast-11, HER2CLIMB-05, PATINA: Dr. Harold BursteinOncology Brothers · 05/01/2026 · 23:04 · apoio da indústriaTriple Negative Breast Cancer SABCS 2025 Highlights: Dr. Rebecca ShatskyOncology Brothers · 03/01/2026 · 24:39 · apoio da indústriaMetastatic HR+ Breast Cancer SABCS 2025 Highlights: Dr. Hope RugoOncology Brothers · 26/12/2025 · 23:34 · apoio da indústriaReal-world outcomes with 1L regimens in HER2+ metastatic breast cancerVJOncology · 23/12/2025 · 2:23 · apoio da indústriaAge at diagnosis and outcomes in young BRCA-associated breast cancerVJOncology · 23/12/2025 · 1:36 · apoio da indústriaReal-world use, disparities and outcomes of neoadjuvant chemo-IO in TNBCVJOncology · 23/12/2025 · 2:28 · apoio da indústriaReal-world outcomes challenge sequential TOP1-ADCs in HER2-low breast cancerVJOncology · 23/12/2025 · 2:32 · apoio da indústriaOmitting sentinel node biopsy in early breast cancer: 5-year BOOG 2013-08 dataVJOncology · 23/12/2025 · 4:53 · apoio da indústriaEarly HR+ Disease SABCS 2025 Practice Changing/Informing Highlights: ALTTO, lidERA, NATALEEOncology Brothers · 22/12/2025 · 15:51 · apoio da indústriaHighlights from SABCS 2025VJOncology · 18/12/2025 · 13:53 · apoio da indústriaERADICATE: elacestrant plus trastuzumab deruxtecan in HR+/HER2-low mBCVJOncology · 15/12/2025 · 1:34 · apoio da indústriaTreatment landscape post-CDK4/6 inhibitors in HR+/HER2-low metastatic breast cancerVJOncology · 15/12/2025 · 1:27 · apoio da indústriaDefining HER2-ultralow breast cancer and its clinical significanceVJOncology · 15/12/2025 · 1:09 · apoio da indústriaAI identifies high-risk lobular breast cancer patients in TAILORxVJOncology · 15/12/2025 · 3:47 · apoio da indústriaManual, digital, and AI TILs scoring in HER2+ breast cancer: APHINITY trialVJOncology · 15/12/2025 · 3:05 · apoio da indústriaALTTO explanatory analysis: adjuvant AI or tamoxifen in pts with HR+/HER2+ early breast cancerVJOncology · 15/12/2025 · 3:07 · apoio da indústriaPREFER: fertility & ovarian function preservation in premenopausal women with early breast cancerVJOncology · 15/12/2025 · 3:11 · apoio da indústriaAddressing health disparities in AI development for breast cancerVJOncology · 15/12/2025 · 1:27 · apoio da indústriaMultimodal AI predicts breast cancer recurrence in TAILORxVJOncology · 15/12/2025 · 2:13 · apoio da indústriaSETER/PR index predicts benefit from extended ELT in HR+ breast cancerVJOncology · 12/12/2025 · 3:26 · apoio da indústriaEthical implementation of artificial intelligence tools in breast cancerVJOncology · 12/12/2025 · 1:30 · apoio da indústriaI-SPY 2: early treatment symptoms predict pCR in high-risk breast cancerVJOncology · 12/12/2025 · 2:15 · apoio da indústriaSmart pill bottles improve adherence to adjuvant ET in breast cancerVJOncology · 12/12/2025 · 1:52 · apoio da indústriaA deep learning model predicts late distant recurrence in HR+ early breast cancerVJOncology · 12/12/2025 · 4:03 · apoio da indústriaLEADER: ribociclib plus endocrine therapy reduces ctDNA in high-risk ER+/HER2- early breast cancerVJOncology · 12/12/2025 · 2:23 · apoio da indústriaEarly breast cancer recurrence predicted by tissue-free ctDNA assayVJOncology · 11/12/2025 · 1:32 · apoio da indústriaSequencing HER2+ therapies in breast cancer: insights on ADCs, TKIs, chemo, & maintenance strategiesVJOncology · 11/12/2025 · 1:25 · apoio da indústriaHER2CLIMB-05: tucatinib improves progression-free survival in HER2+ metastatic breast cancerVJOncology · 10/12/2025 · 2:08 · apoio da indústrialidERA trial: giredestrant improves invasive disease-free survival in ER+/HER2- early breast cancerVJOncology · 10/12/2025 · 3:01 · apoio da indústriaConferência Brasileira de Câncer de Mama Best of SABCS - Edição 2025LACOG · 05/11/2025 · 2:00Attend the NCCN 2026 Breast Cancer Congress for Clinical Updates and Expert InsightsNCCN · 02/10/2025 · 2:06